Sushmita Chanda

机构：Rapt Therapeutics (United States), Denali Therapeutics (United States)

发表论文 88 篇 · 总被引 1958 次 · h-index 21

代表论文

• Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH (2024 · Journal of Medicinal Chemistry · 被引 35)
• The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075 (2024 · Journal of Medicinal Chemistry · 被引 28)
• Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models (2023 · International Journal of Molecular Sciences · 被引 18)
• ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 5)
• Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor (2025 · Journal of Medicinal Chemistry · 被引 4)
• A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants (2025 · Antiviral Therapy · 被引 3)